NASDAQ:JAZZJazz Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Jazz Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $119.09 -0.23 (-0.19 %) (As of 06/1/2020 01:19 PM ET) Add Compare Share Today's Range$118.87Now: $119.09▼$120.6850-Day Range$102.44MA: $110.22▼$118.7952-Week Range$86.88Now: $119.09▼$154.24Volume7,710 shsAverage Volume484,692 shsMarket Capitalization$6.59 billionP/E Ratio24.76Dividend YieldN/ABeta1.23 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also develops Solriamfetol for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea, as well as in Phase II clinical trial for EDS associated with Parkinson's disease; Vyxeos for acute myeloid leukemia; and JZP-258 to treat EDS and cataplexy with narcolepsy and potential treatment of idiopathic hypersomnia and a chronic neurological disorder. In addition, it sells psychiatry and other products. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; and XL-protein GmbH. The company is headquartered in Dublin, Ireland.Read More Beat the Market (BTM) Rank™ 4.3 Analyst's Opinion Consensus RatingJazz Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.68, and is based on 13 buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $156.72, Jazz Pharmaceuticals has a potential upside of 31.4% from its current price of $119.25.Amount of Analyst CoverageJazz Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.4 Community Rank Outperform VotesJazz Pharmaceuticals has received 970 “outperform” votes. (Add your “outperform” vote.)Underperform VotesJazz Pharmaceuticals has received 457 “underperform” votes. (Add your “underperform” vote.)Community SentimentJazz Pharmaceuticals has received 67.97% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Jazz Pharmaceuticals and other stocks. Vote “Outperform” if you believe JAZZ will outperform the S&P 500 over the long term. Vote “Underperform” if you believe JAZZ will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldJazz Pharmaceuticals does not currently pay a dividend.Dividend GrowthJazz Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Jazz Pharmaceuticals insiders have bought 1,143.07% more of their company's stock than they have sold. Specifically, they have bought $5,865,500.00 in company stock and sold $471,855.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Jazz Pharmaceuticals is held by insiders.Percentage Held by Institutions89.14% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Jazz Pharmaceuticals are expected to grow by 48.47% in the coming year, from $9.82 to $14.58 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jazz Pharmaceuticals is 24.79, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.48.Price to Earnings Ratio vs. SectorThe P/E ratio of Jazz Pharmaceuticals is 24.79, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 25.36.Price to Earnings Growth RatioJazz Pharmaceuticals has a PEG Ratio of 1.37. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioJazz Pharmaceuticals has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.3Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 2.5 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.85 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:JAZZ Previous Symbol CUSIPG5087110 CIK1232524 Webwww.jazzpharma.com Phone011-353-1634-7800Debt Debt-to-Equity Ratio0.61 Current Ratio3.83 Quick Ratio3.62Price-To-Earnings Trailing P/E Ratio24.76 Forward P/E Ratio12.13 P/E Growth1.37 Sales & Book Value Annual Sales$2.16 billion Price / Sales3.05 Cash Flow$22.18 per share Price / Cash Flow5.37 Book Value$54.99 per share Price / Book2.17Profitability EPS (Most Recent Fiscal Year)$14.60 Net Income$523.37 million Net Margins12.81% Return on Equity21.66% Return on Assets11.90%Miscellaneous Employees1,620 Outstanding Shares55,330,000Market Cap$6.59 billion Next Earnings Date8/4/2020 (Estimated) OptionableOptionable NASDAQ:JAZZ Rates by TradingView Receive JAZZ News and Ratings via Email Sign-up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter. Jazz Pharmaceuticals (NASDAQ:JAZZ) Frequently Asked Questions How has Jazz Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Jazz Pharmaceuticals' stock was trading at $108.04 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, JAZZ stock has increased by 10.4% and is now trading at $119.2450. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Jazz Pharmaceuticals? 19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 6 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Jazz Pharmaceuticals. When is Jazz Pharmaceuticals' next earnings date? Jazz Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Jazz Pharmaceuticals. How were Jazz Pharmaceuticals' earnings last quarter? Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) issued its earnings results on Tuesday, May, 5th. The specialty pharmaceutical company reported $0.45 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.21 by $0.24. The specialty pharmaceutical company earned $534.73 million during the quarter, compared to analyst estimates of $544.55 million. Jazz Pharmaceuticals had a net margin of 12.81% and a return on equity of 21.66%. The business's revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the prior year, the business earned $3.67 EPS. View Jazz Pharmaceuticals' earnings history. What guidance has Jazz Pharmaceuticals issued on next quarter's earnings? Jazz Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, May, 5th. The company provided earnings per share (EPS) guidance of 11.25-12.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $12.31. The company issued revenue guidance of $2.12-2.26 billion, compared to the consensus revenue estimate of $2.3 billion. What price target have analysts set for JAZZ? 19 brokerages have issued 12 month target prices for Jazz Pharmaceuticals' stock. Their forecasts range from $109.00 to $200.00. On average, they anticipate Jazz Pharmaceuticals' share price to reach $156.72 in the next year. This suggests a possible upside of 31.4% from the stock's current price. View analysts' price targets for Jazz Pharmaceuticals. What are Wall Street analysts saying about Jazz Pharmaceuticals stock? Here are some recent quotes from research analysts about Jazz Pharmaceuticals stock: 1. According to Zacks Investment Research, "Jazz’s key drug, Xyrem, continues to witness improved volume trends in 2019 on the back of awareness efforts. The label expansion of Xyrem in pediatric patients has improved the top line further. Management expects Xyrem's volume growth to continue in the second half. Sunosi's launch in July 2019 complements the sleep franchise and its successful commercialization may offset a decline in Xyrem’s sales following patent expiry in 2023. Jazz’s leukemia drug, Vyxeos, has also witnessed strong growth so far in 2019. Its launch in Europe boosted sales in 2019. However, Jazz has been facing supply crunch for its leukemia drug, Erwinaze, owing to constrained manufacturing capacity, which is likely to continue in second half. Defitelio sales also vary every quarter." (9/13/2019) 2. HC Wainwright analysts commented, "Our $147 12-month target (from $153) is based on a DCF, which reflects a strong 15% 2019-22 cash- flow CAGR, a 10% WACC discount rate, and negative 3.5% terminal growth after 2022 given conservatively assumed modest Xyrem franchise headwinds partially offset by other products’ continued growth." (8/8/2019) Has Jazz Pharmaceuticals been receiving favorable news coverage? Media coverage about JAZZ stock has been trending somewhat positive this week, InfoTrie reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Jazz Pharmaceuticals earned a news sentiment score of 1.0 on InfoTrie's scale. They also assigned media coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutJazz Pharmaceuticals. Are investors shorting Jazz Pharmaceuticals? Jazz Pharmaceuticals saw a decline in short interest in May. As of May 15th, there was short interest totaling 2,790,000 shares, a decline of 5.4% from the April 30th total of 2,950,000 shares. Based on an average trading volume of 693,300 shares, the short-interest ratio is presently 4.0 days. Currently, 5.2% of the shares of the company are short sold. View Jazz Pharmaceuticals' Current Options Chain. Who are some of Jazz Pharmaceuticals' key competitors? Some companies that are related to Jazz Pharmaceuticals include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors. What other stocks do shareholders of Jazz Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), NVIDIA (NVDA), Tesla (TSLA), Visa (V), Bank of America (BAC) and Biogen (BIIB). Who are Jazz Pharmaceuticals' key executives? Jazz Pharmaceuticals' management team includes the following people: Mr. Bruce C. Cozadd, Co-Founder, Chairman & CEO (Age 55)Mr. Matthew P. Young, Exec. VP & CFO (Age 50)Mr. Daniel N. Swisher Jr., Pres & COO (Age 56)Ms. Karen J. Wilson, Sr. VP of Fin. & Principal Accounting Officer (Age 56)Mr. Paul Treacy, Sr. VP of Technical Operations (Age 58) What is Jazz Pharmaceuticals' stock symbol? Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ." Who are Jazz Pharmaceuticals' major shareholders? Jazz Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.15%), AQR Capital Management LLC (4.25%), JPMorgan Chase & Co. (3.19%), Nuveen Asset Management LLC (2.96%), State Street Corp (2.72%) and Janus Henderson Group PLC (1.49%). Company insiders that own Jazz Pharmaceuticals stock include Bruce C Cozadd, Catherine A Sohn, Finbar Larkin, Kenneth W O'keefe, Matthew P Young, Michael Patrick Miller, Patricia Carr, Patrick G Enright, Paul Treacy, Rick E Winningham, Seamus Mulligan and Suzanne Sawochka Hooper. View institutional ownership trends for Jazz Pharmaceuticals. Which institutional investors are selling Jazz Pharmaceuticals stock? JAZZ stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, BlackRock Inc., Assenagon Asset Management S.A., JPMorgan Chase & Co., Nuveen Asset Management LLC, KBC Group NV, Wellington Management Group LLP, and AJO LP. Company insiders that have sold Jazz Pharmaceuticals company stock in the last year include Bruce C Cozadd, Catherine A Sohn, Finbar Larkin, Kenneth W O'keefe, Michael Patrick Miller, Patricia Carr, and Paul Treacy. View insider buying and selling activity for Jazz Pharmaceuticals. Which institutional investors are buying Jazz Pharmaceuticals stock? JAZZ stock was acquired by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Sarissa Capital Management LP, APG Asset Management N.V., Janus Henderson Group PLC, PNC Financial Services Group Inc., First Trust Advisors LP, Robeco Institutional Asset Management B.V., and Systematic Financial Management LP. View insider buying and selling activity for Jazz Pharmaceuticals. How do I buy shares of Jazz Pharmaceuticals? Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Jazz Pharmaceuticals' stock price today? One share of JAZZ stock can currently be purchased for approximately $119.25. How big of a company is Jazz Pharmaceuticals? Jazz Pharmaceuticals has a market capitalization of $6.60 billion and generates $2.16 billion in revenue each year. The specialty pharmaceutical company earns $523.37 million in net income (profit) each year or $14.60 on an earnings per share basis. Jazz Pharmaceuticals employs 1,620 workers across the globe. What is Jazz Pharmaceuticals' official website? The official website for Jazz Pharmaceuticals is www.jazzpharma.com. How can I contact Jazz Pharmaceuticals? Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at 011-353-1634-7800 or via email at [email protected] This page was last updated on 6/1/2020 by MarketBeat.com Staff
